medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (2)


Recent Advances in Hepatotoxicity of Non Steroidal Anti-inflammatory Drugs

Meunier L, Larrey D

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 187-191
Archivo PDF: 126.88 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lewis JH, Stine JG. Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists. In: Drug-induced liver disease. Eds. Kaplowitz N, DeLeve DL. Third Ed. Amsterdam, Boston, London, New-York, Oxford, Paris: 2013; pp. 369- 401.

  2. Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003; 12: 315-26.

  3. Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci 2016; 17: 224-31.

  4. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, Garcia-Munoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.

  5. Gulmez SE, Larrey D, Pageaux G-P, Lignot S, Lassalle R, Jové J, Gatta A, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36: 135-44.

  6. Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, Russo MW, et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int Off J Int Assoc Study Liver 2016; 36: 603?9.

  7. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis 2013; 17: 643-56.

  8. LiverTox: http://livertox.nlm.nih.gov.

  9. Larrey D, Ursic-Bedoya J, Meunier L. Drug-Induced hepatotoxicity. In: Schiff ER, editor. Schiff 's diseases of the liver. 12th Ed. New York: Wiley- Blackwell; 2018, pp. 740-73.

  10. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430-40.

  11. Pillans PI, Ghiculescu RA, Lampe G, Wilson R, Wong R, Macdonald GA. Severe acute liver injury associated with lumiracoxib. J Gastroenterol Hepatol 2012; 27: 1102-5.

  12. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248-55.

  13. Danan G, Teschke R. RUCAM in drug and herb-induced liver: the update. Int J Mol Sci 2015; 17,pii; E14. doi: 10.3390/ ijms17010014

  14. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.

  15. Teschke R, Frenzel C. Drug induced liver injury: Do we still need a routine liver biopsy for diagnosis today? Ann Hepatol 2014, 13: 121-7.

  16. Larrey D, Meunier L, Ursic-Bedoya J. Liver biopsy in chronic liver diseases: is there a favorable benefit: risk balance? Ann Hepatol 2017; 16: 487-9. doi: 10.5604/ 01.3001.0010.0272.

  17. Teschcke R, Schulze J, Eickhoff A, Danan G. Drug Induced Liver Injury: can biomarkers Assist RUCAM in causality Assessment? Int J Mol Sci 2017; 18: 803;doi:10.3390/ijms 18040803.

  18. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154-64.

  19. 19 Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625-34.

  20. 20 Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, et al. International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology 2017; 152: 1078-89.




2020     |     www.medigraphic.com